MAP microba life sciences limited

Ann: Q4 FY25 Quarterly Activities Report & Appendix 4C, page-5

  1. 327 Posts.
    lightbulb Created with Sketch. 72
    forget about the increase in COGs as a % of sales.
    forget about the fact they don’t report dollars for the test business and only report volume currently.
    forget they said they would have ample capital less than 2 years ago.
    forget that their business is actually not growing, and they only acquired the UK business half way through FY24, which means their reported number isn’t a true reflection of performance. Looking at their quarterly number and the last 6 months they aren’t really growing sales.

    the question is, what happens if they aren’t able to grow ~100% in testing sales in the next 12 months and deliver on the break even promise for the countries? Should we be pricing in another raise at 20-30% discount?
    how will sonic respond who has committed $30m and the business will be worth about $30m by then, then means they lost 75% of their investment…. Do they take it over at a discount or just walk away knowing they learnt a lot which they can deploy in their business as needed.

    im holding but if they don’t deliver a good quarterly, then we must reconsider as retail holders that we don’t get screwed.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.6¢
Change
0.001(1.05%)
Mkt cap ! $49.44M
Open High Low Value Volume
9.5¢ 9.9¢ 9.3¢ $42.31K 440.9K

Buyers (Bids)

No. Vol. Price($)
1 10250 9.2¢
 

Sellers (Offers)

Price($) Vol. No.
9.7¢ 40000 1
View Market Depth
Last trade - 15.55pm 25/07/2025 (20 minute delay) ?
MAP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.